- Home
- REX vs GHRS Comparison
REX vs GHRS Comparison
Compare REX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | GHRS |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REX | GHRS |
|---|---|---|
| Price | $39.48 | $15.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $25.00 | ★ $40.33 |
| AVG Volume (30 Days) | 133.4K | ★ 180.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $642,491,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $17.11 | N/A |
| P/E Ratio | $33.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.02 | $7.98 |
| 52 Week High | $64.95 | $19.51 |
Technical Indicators
Market Signals| Indicator | REX | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 74.43 | 49.27 |
| Support Level | $38.88 | $12.04 |
| Resistance Level | $43.62 | $16.22 |
| Average True Range (ATR) | 1.21 | 0.91 |
| MACD | 0.40 | -0.03 |
| Stochastic Oscillator | 86.48 | 49.76 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.